PGE1 as Additive Anticoagulant in ECMO-Therapy (ECMO_PGE1)
A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)
Sponsor: Thomas Staudinger
Terminated
After completion of pilot study (n=50) no effect on primary outcome and limited feasibility of recruitment and study procedures
A PHASE2 clinical study on Extracorporeal Membrane Oxygenation and Respiratory Distress Syndrome, Adult, this trial is terminated or withdrawn. The trial is conducted by Thomas Staudinger and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Jan 2021 — Mar 2022 [monthly]
Unknown Status PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Sep 2018 — Sep 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Thomas Staudinger
For direct contact, visit the study record on ClinicalTrials.gov .